老年女性乳腺癌患者的合并症数量对辅助治疗耐受性和生存的影响  

Impact of Comorbidities on Treating Tolerance and Survival in Elderly Patients with Breast Cancer

作　　者：徐蓓[1] 金文[1] 李倩[1] 周宇红[1] 刘天舒[1] 

机构地区：[1]复旦大学附属中山医院肿瘤内科,上海200032

出　　处：《中国临床医学》2015年第3期363-366,共4页Chinese Journal of Clinical Medicine

基　　金：国家自然科学基金(编号:81101498)

摘　　要：目的：探讨老年女性乳腺癌患者的常见合并疾病对术后辅助化疗和（或）内分泌治疗的治疗耐受性和生存的影响。方法：将2012年1月—2012年12月在复旦大学附属中山医院行手术治疗的52例老年女性乳腺癌患者按照合并疾病数量分为2组（伴有0-1个合并症组和≥2个合并症组）,分析临床和病理特征与患者生存和预后的相关性。结果：0-1个合并症组和≥2个合并症组复发率、病死率、无疾病生存期（drease free survival,DFS）和总生存期（overall survival,OS）的差异均无统计学意义（P分别为0.666、1.000、0.347、0.562）。结论：合并症的数量与老年女性乳腺癌患者的生存期、治疗耐受性无明显相关性。Objective：To investigate the effect of comorbidities on tolerance and survival of elderly female patients with breast cancer undergoing adjuvant chemotherapy and/or endocrine therapy.Methods：According to the number of comorbidities,52 breast cancer patients were divided into 2 groups（0-1 complication group and more than 2 complication group）.All patients were old female received operation in Zhongshan Hospital,Fudan University from2012 January to 2012 December.The relationship of patient clinical and pathological characteristics and survival were analyzed between the two groups.Results：No statistical difference in the recurrence rate,mortality,disease free survival（DFS）and overall survival（OS）were found（P=0.666,1.000,0.347 and 0.562）between the two groups.Conclusions：Comorbidities may not strongly associated with risk of shorter survival and worse treatment tolerance for elderly female breast cancer patients.

关 键 词：乳腺癌 合并疾病 术后辅助治疗 生存期 

分 类 号：TP737.9[自动化与计算机技术—检测技术与自动化装置]